FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904010305> ?p ?o ?g. }

• W2904010305 endingPage "e24" @default.
• W2904010305 startingPage "e15" @default.
• W2904010305 abstract "Background Current treatment for HIV-infected individuals with renal failure on haemodialysis frequently requires complex regimens with multiple pills. A daily single-tablet regimen of coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide is approved in Europe, the USA, and in other regions for use in HIV-1-infected individuals with mild-to-moderate chronic kidney disease (creatinine clearance 30–69 mL/min). We aimed to assess the safety, efficacy, and pharmacokinetics of this regimen in HIV-infected adults with end-stage renal disease on chronic haemodialysis. Methods We did an open-label, single-arm, multicentre, phase 3b trial at 26 outpatient clinics in Austria, France, Germany, and the USA. Participants were HIV-1-infected adults with end-stage renal disease (creatinine clearance <15 mL/min), on chronic haemodialysis for at least 6 months before screening. Virological suppression (ie, plasma HIV-1 RNA <50 copies per mL) on a stable antiretroviral regimen was required for at least 6 months before screening with a CD4 count of at least 200 cells per μL. We switched all participants to coformulated elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg once daily, taken after haemodialysis for up to 96 weeks. We did assessments at study visits at weeks 2, 4, 8, 12, 24, 36, and 48, and every 12 weeks thereafter up to 96 weeks. The primary endpoint was the incidence of treatment-emergent adverse events of grade 3 or higher up to week 48. All participants who received at least one dose of study drug were included in the primary analysis. This study is registered with ClinicalTrials.gov (NCT02600819) and is closed to new participants. Findings Between Feb 1, and Nov 3, 2016, 55 participants were enrolled and received at least one dose of study drug. Through week 48, 18 of 55 participants (33%, 95% CI 20–45) had an adverse event of grade 3 or higher on study treatment. Treatment-emergent grade 3 or higher adverse events that occurred in more than one participant included anaemia, osteomyelitis, prolonged electrocardiogram QT, fluid overload, hyperkalaemia, hypertension, and hypotension (all n=2). No adverse event of grade 3 or higher was considered by the site investigators to be treatment related. Three participants (5%, 95% CI 0–11) discontinued treatment because of adverse events; one of these (grade 1 allergic pruritus) was considered treatment related. Treatment-related adverse events were reported for six individuals (11%, 95% CI 3–19), the most common of which was nausea (in four individuals [7%]); all treatment-related adverse events were grade 1 or 2 in severity. Interpretation At 48 weeks, switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide was well tolerated. This regimen might provide a tolerable and convenient option for ongoing treatment of HIV-1 infection in adults with end-stage renal disease on chronic haemodialysis. Funding Gilead Sciences." @default.
• W2904010305 created "2018-12-22" @default.
• W2904010305 creator A5000420787 @default.
• W2904010305 creator A5001632717 @default.
• W2904010305 creator A5004012561 @default.
• W2904010305 creator A5005486541 @default.
• W2904010305 creator A5010850224 @default.
• W2904010305 creator A5013665356 @default.
• W2904010305 creator A5015389391 @default.
• W2904010305 creator A5021000769 @default.
• W2904010305 creator A5024560316 @default.
• W2904010305 creator A5029596685 @default.
• W2904010305 creator A5033466901 @default.
• W2904010305 creator A5063249733 @default.
• W2904010305 creator A5065954575 @default.
• W2904010305 creator A5076529428 @default.
• W2904010305 creator A5080474527 @default.
• W2904010305 creator A5080950921 @default.
• W2904010305 creator A5088424983 @default.
• W2904010305 date "2019-01-01" @default.
• W2904010305 modified "2023-09-25" @default.
• W2904010305 title "Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial" @default.
• W2904010305 cites W1976985937 @default.
• W2904010305 cites W2017605567 @default.
• W2904010305 cites W2021558850 @default.
• W2904010305 cites W2035226075 @default.
• W2904010305 cites W2076175848 @default.
• W2904010305 cites W2094241860 @default.
• W2904010305 cites W2102951977 @default.
• W2904010305 cites W2103115327 @default.
• W2904010305 cites W2106473738 @default.
• W2904010305 cites W2121036476 @default.
• W2904010305 cites W2135397849 @default.
• W2904010305 cites W2149185709 @default.
• W2904010305 cites W2150585325 @default.
• W2904010305 cites W2183163677 @default.
• W2904010305 cites W2186174256 @default.
• W2904010305 cites W2301510887 @default.
• W2904010305 cites W2313051027 @default.
• W2904010305 cites W2331357572 @default.
• W2904010305 cites W2344572331 @default.
• W2904010305 cites W2422087709 @default.
• W2904010305 cites W2467247336 @default.
• W2904010305 cites W2581081094 @default.
• W2904010305 cites W2591030999 @default.
• W2904010305 cites W2625077955 @default.
• W2904010305 cites W2753489952 @default.
• W2904010305 cites W2761345412 @default.
• W2904010305 cites W2783198041 @default.
• W2904010305 cites W2795476651 @default.
• W2904010305 doi "https://doi.org/10.1016/s2352-3018(18)30296-0" @default.
• W2904010305 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30555051" @default.
• W2904010305 hasPublicationYear "2019" @default.
• W2904010305 type Work @default.
• W2904010305 sameAs 2904010305 @default.
• W2904010305 citedByCount "17" @default.
• W2904010305 countsByYear W29040103052019 @default.
• W2904010305 countsByYear W29040103052020 @default.
• W2904010305 countsByYear W29040103052021 @default.
• W2904010305 countsByYear W29040103052022 @default.
• W2904010305 crossrefType "journal-article" @default.
• W2904010305 hasAuthorship W2904010305A5000420787 @default.
• W2904010305 hasAuthorship W2904010305A5001632717 @default.
• W2904010305 hasAuthorship W2904010305A5004012561 @default.
• W2904010305 hasAuthorship W2904010305A5005486541 @default.
• W2904010305 hasAuthorship W2904010305A5010850224 @default.
• W2904010305 hasAuthorship W2904010305A5013665356 @default.
• W2904010305 hasAuthorship W2904010305A5015389391 @default.
• W2904010305 hasAuthorship W2904010305A5021000769 @default.
• W2904010305 hasAuthorship W2904010305A5024560316 @default.
• W2904010305 hasAuthorship W2904010305A5029596685 @default.
• W2904010305 hasAuthorship W2904010305A5033466901 @default.
• W2904010305 hasAuthorship W2904010305A5063249733 @default.
• W2904010305 hasAuthorship W2904010305A5065954575 @default.
• W2904010305 hasAuthorship W2904010305A5076529428 @default.
• W2904010305 hasAuthorship W2904010305A5080474527 @default.
• W2904010305 hasAuthorship W2904010305A5080950921 @default.
• W2904010305 hasAuthorship W2904010305A5088424983 @default.
• W2904010305 hasBestOaLocation W29040103052 @default.
• W2904010305 hasConcept C126322002 @default.
• W2904010305 hasConcept C141071460 @default.
• W2904010305 hasConcept C142462285 @default.
• W2904010305 hasConcept C159641895 @default.
• W2904010305 hasConcept C203014093 @default.
• W2904010305 hasConcept C2777068322 @default.
• W2904010305 hasConcept C2778063415 @default.
• W2904010305 hasConcept C2778653478 @default.
• W2904010305 hasConcept C2779778239 @default.
• W2904010305 hasConcept C2780524789 @default.
• W2904010305 hasConcept C2781413609 @default.
• W2904010305 hasConcept C2911190787 @default.
• W2904010305 hasConcept C2993143319 @default.
• W2904010305 hasConcept C3013748606 @default.
• W2904010305 hasConcept C3019040382 @default.
• W2904010305 hasConcept C71924100 @default.
• W2904010305 hasConceptScore W2904010305C126322002 @default.
• W2904010305 hasConceptScore W2904010305C141071460 @default.
• W2904010305 hasConceptScore W2904010305C142462285 @default.

• next